-$0.07 Earnings Per Share Expected for Mediwound Ltd (NASDAQ:MDWD) This Quarter

Brokerages predict that Mediwound Ltd (NASDAQ:MDWD) will announce earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Mediwound’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.08). Mediwound posted earnings per share of ($0.11) during the same quarter last year, which suggests a positive year over year growth rate of 36.4%. The business is scheduled to report its next earnings results on Thursday, November 12th.

According to Zacks, analysts expect that Mediwound will report full-year earnings of ($0.40) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.34). For the next year, analysts forecast that the business will report earnings of ($0.21) per share, with EPS estimates ranging from ($0.29) to ($0.10). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Mediwound.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.11). Mediwound had a negative return on equity of 85.28% and a negative net margin of 48.34%. The company had revenue of $4.03 million during the quarter, compared to analysts’ expectations of $4.79 million.

A number of analysts have commented on MDWD shares. TheStreet cut Mediwound from a “c-” rating to an “e+” rating in a research report on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating on shares of Mediwound in a research report on Friday, August 7th. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Saturday, June 20th. Oppenheimer reaffirmed a “buy” rating and set a $7.00 target price on shares of Mediwound in a report on Tuesday, June 30th. Finally, ValuEngine cut shares of Mediwound from a “buy” rating to a “hold” rating in a research note on Tuesday, July 7th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. Mediwound currently has an average rating of “Buy” and a consensus target price of $5.17.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its holdings in Mediwound by 15.8% in the 1st quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 29,911 shares during the period. Sargent Investment Group LLC increased its stake in Mediwound by 45.6% during the second quarter. Sargent Investment Group LLC now owns 170,900 shares of the biopharmaceutical company’s stock worth $569,000 after purchasing an additional 53,500 shares during the period. Acadian Asset Management LLC increased its stake in Mediwound by 136.4% during the first quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 75,045 shares during the period. Phoenix Holdings Ltd. purchased a new stake in Mediwound during the second quarter worth about $313,000. Finally, Fortis Advisors LLC purchased a new stake in Mediwound during the first quarter worth about $108,000. Hedge funds and other institutional investors own 16.69% of the company’s stock.

MDWD traded up $0.08 on Wednesday, reaching $3.80. 442,941 shares of the stock were exchanged, compared to its average volume of 110,982. The company’s 50-day moving average price is $3.55 and its 200 day moving average price is $2.64. Mediwound has a fifty-two week low of $1.44 and a fifty-two week high of $4.44. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.05 and a quick ratio of 2.85. The firm has a market capitalization of $103.40 million, a PE ratio of -11.32 and a beta of 1.63.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Story: What is Liquidity?

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.